Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://saludpublica.mx
Are you over 18 and want to see adult content?
A complete backup of https://elliottmurphy.com
Are you over 18 and want to see adult content?
A complete backup of https://unboundmedicine.com
Are you over 18 and want to see adult content?
A complete backup of https://iremember.ru
Are you over 18 and want to see adult content?
A complete backup of https://apachefriends.org
Are you over 18 and want to see adult content?
A complete backup of https://matteboken.se
Are you over 18 and want to see adult content?
A complete backup of https://standout-cabin-designs.com
Are you over 18 and want to see adult content?
A complete backup of https://ethicalseoconsulting.com
Are you over 18 and want to see adult content?
A complete backup of https://interplasinsights.com
Are you over 18 and want to see adult content?
A complete backup of https://abilkhair.org
Are you over 18 and want to see adult content?
A complete backup of https://infobizz.co.in
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of amerrymishapblog.com
Are you over 18 and want to see adult content?
A complete backup of alles-zur-allergologie.de
Are you over 18 and want to see adult content?
A complete backup of checkartstudio.com
Are you over 18 and want to see adult content?
A complete backup of sauna-ikitai.com
Are you over 18 and want to see adult content?
A complete backup of yeahilift.tumblr.com
Are you over 18 and want to see adult content?
A complete backup of autovillage.co.uk
Are you over 18 and want to see adult content?
A complete backup of olimpiadadehistoria.com.br
Are you over 18 and want to see adult content?
A complete backup of nerdvanamedia.com
Are you over 18 and want to see adult content?
Text
WWW.DRUGBANK.CA
www.drugbank.ca
INFLUENZA A VIRUS A/BRISBANE/10/2010 (H1N1) ANTIGEN (MDCK A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen".TINNITUS - DRUGBANK
Drug Drug Name Target Type; Drug Drug Name Phase Status Count; DB00281: Lidocaine: 0: Completed: 1: DB00281: Lidocaine UDP-GLUCURONOSYLTRANSFERASE 1-4 cellular glucuronidation / cellular response to hormone stimulus / flavonoid biosynthetic process / flavonoid glucuronidation / heme catabolic process / negative regulation of cellular glucuronidation / negative regulation of fatty acid metabolic process / negative regulation of glucuronosyltransferase activity / porphyrin-containing compound metabolic process / small molecule metabolic SHOWING BIOINTERACTIONS FOR CARTEOLOL (DB00521) BioInteractor utilizes data on drug-target, -enzyme and -transporter associations to provide insight on drug-drug interactions. It allows you to identify, for instance, which drugs act similarly on the same target. Such drugs may have additive pharmacodynamic effects if givenconcomitantly.
SHOWING BIOINTERACTIONS FOR VOGLIBOSE (DB04878) This project is supported by the Canadian Institutes of Health Research (award #111062), Alberta Innovates - Health Solutions, and by The Metabolomics Innovation Centre (TMIC), a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies.TMIC is funded by Genome Alberta, Genome British Columbia, and Genome Canada, a not-for-profitWWW.DRUGBANK.CA
www.drugbank.ca
INFLUENZA A VIRUS A/BRISBANE/10/2010 (H1N1) ANTIGEN (MDCK A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen".TINNITUS - DRUGBANK
Drug Drug Name Target Type; Drug Drug Name Phase Status Count; DB00281: Lidocaine: 0: Completed: 1: DB00281: Lidocaine UDP-GLUCURONOSYLTRANSFERASE 1-4 cellular glucuronidation / cellular response to hormone stimulus / flavonoid biosynthetic process / flavonoid glucuronidation / heme catabolic process / negative regulation of cellular glucuronidation / negative regulation of fatty acid metabolic process / negative regulation of glucuronosyltransferase activity / porphyrin-containing compound metabolic process / small molecule metabolic SHOWING BIOINTERACTIONS FOR CARTEOLOL (DB00521) BioInteractor utilizes data on drug-target, -enzyme and -transporter associations to provide insight on drug-drug interactions. It allows you to identify, for instance, which drugs act similarly on the same target. Such drugs may have additive pharmacodynamic effects if givenconcomitantly.
SHOWING BIOINTERACTIONS FOR VOGLIBOSE (DB04878) This project is supported by the Canadian Institutes of Health Research (award #111062), Alberta Innovates - Health Solutions, and by The Metabolomics Innovation Centre (TMIC), a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies.TMIC is funded by Genome Alberta, Genome British Columbia, and Genome Canada, a not-for-profitWWW.DRUGBANK.CA
www.drugbank.ca
INFLUENZA A VIRUS A/BRISBANE/10/2010 (H1N1) ANTIGEN (MDCK A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen".WWW.DRUGBANK.CA
710 mrv0541 02241213162d 32 37 0 0 0 0 999 v2000 -2.0879 -1.1454 0.0000 c 0 0 0 0 0 0 0 0 0 0 0 0 -2.8725 -0.8905 0.0000 c 0 0 0 0 0 0 0 0 0 0 0 0 -3.0440 -0.0835 0TINNITUS - DRUGBANK
Website design by Educe Design & Innovation Inc. UDP-GLUCURONOSYLTRANSFERASE 1-4 cellular glucuronidation / cellular response to hormone stimulus / flavonoid biosynthetic process / flavonoid glucuronidation / heme catabolic process / negative regulation of cellular glucuronidation / negative regulation of fatty acid metabolic process / negative regulation of glucuronosyltransferase activity / porphyrin-containing compound metabolic process / small molecule metabolic SHOWING BIOINTERACTIONS FOR CARTEOLOL (DB00521) BioInteractor utilizes data on drug-target, -enzyme and -transporter associations to provide insight on drug-drug interactions. It allows you to identify, for instance, which drugs act similarly on the same target. Such drugs may have additive pharmacodynamic effects if givenconcomitantly.
SHOWING BIOINTERACTIONS FOR VOGLIBOSE (DB04878) This project is supported by the Canadian Institutes of Health Research (award #111062), Alberta Innovates - Health Solutions, and by The Metabolomics Innovation Centre (TMIC), a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies.TMIC is funded by Genome Alberta, Genome British Columbia, and Genome Canada, a not-for-profitWWW.DRUGBANK.CA
www.drugbank.ca
INFLUENZA A VIRUS A/BRISBANE/10/2010 (H1N1) ANTIGEN (MDCK A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen".WWW.DRUGBANK.CA
710 mrv0541 02241213162d 32 37 0 0 0 0 999 v2000 -2.0879 -1.1454 0.0000 c 0 0 0 0 0 0 0 0 0 0 0 0 -2.8725 -0.8905 0.0000 c 0 0 0 0 0 0 0 0 0 0 0 0 -3.0440 -0.0835 0TINNITUS - DRUGBANK
Website design by Educe Design & Innovation Inc. UDP-GLUCURONOSYLTRANSFERASE 1-4 cellular glucuronidation / cellular response to hormone stimulus / flavonoid biosynthetic process / flavonoid glucuronidation / heme catabolic process / negative regulation of cellular glucuronidation / negative regulation of fatty acid metabolic process / negative regulation of glucuronosyltransferase activity / porphyrin-containing compound metabolic process / small molecule metabolic SHOWING BIOINTERACTIONS FOR CARTEOLOL (DB00521) BioInteractor utilizes data on drug-target, -enzyme and -transporter associations to provide insight on drug-drug interactions. It allows you to identify, for instance, which drugs act similarly on the same target. Such drugs may have additive pharmacodynamic effects if givenconcomitantly.
SHOWING BIOINTERACTIONS FOR VOGLIBOSE (DB04878) This project is supported by the Canadian Institutes of Health Research (award #111062), Alberta Innovates - Health Solutions, and by The Metabolomics Innovation Centre (TMIC), a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies.TMIC is funded by Genome Alberta, Genome British Columbia, and Genome Canada, a not-for-profit* Browse
Drugs
Categories
Pathways
Drug Reactions
Drug Classification
Drug Targets
Pharmaco-genomics
Pharmaco-metabolomics Pharmaco-transcriptomicsPharmaco-proteomics
* Search
Chemical Structure
Molecular Weight
Drug & Food InteractionsTarget Sequences
Pharmaco-omics
Advanced Search
MS Search
MS/MS Search
GC/MS Search
1D NMR Search
2D NMR Search
* Downloads
* Commercial Data
Products
Clinical Drug Data
Scientific Drug Data IndustriesDrug Discovery Drug Repurposing Precision MedicineMachine Learning
ResourcesWhite Papers* Help
Help Center
Quick Links
Citing DrugBank
DrugBank.ca FAQs
Searching DrugBank
Other Databases
Data Sources
* About
About DrugBank.ca
Statistics
Blog
Wishart Research GroupContact Us
Download our new white paper, COVID-19: Finding the Right FitLearnMore
What are you looking for?Drugs
Targets
Pathways
Indications
The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug data with comprehensive drugtarget information.
The latest release of DrugBank (version 5.1.5, released 2020-01-03) contains 13,533 drug entries including 2,629 approved small molecule drugs, 1,372 approved biologics (proteins, peptides, vaccines, and allergenics), 131 nutraceuticals and over 6,355 experimental (discovery-phase) drugs. Additionally, 5,212 non-redundant protein (i.e. drug target/enzyme/transporter/carrier) sequences are linked to these drug entries. Each entry contains more than 200 data fields with half of the information being devoted to drug/chemical data and the other half devoted to drug target or protein data.About DrugBank
Cite DrugBank
DrugBank for Commercial UseDrugBank top drugs
* MORPHINE
An opioid agonist used for the relief of moderate to severe acute andchronic pain.
* OXYCODONE
An opioid used in the management of moderate to severe pain.* ACETAMINOPHEN
An analgesic drug used alone or in combination with opioids for pain management, and as an antipyretic agent.* CODEINE
An opioid analgesic used to treat moderate to severe pain when the use of an opioid is indicated.* SALBUTAMOL
A beta-2 adrenergic receptor agonist used to treat asthma, bronchitis, COPD, as well as prevent exercise induced bronchospasms. * ACETYLSALICYLIC ACID A salicylate used to treat pain, fever, inflammation, migraines, and reducing the risk of major adverse cardiovascular events. Featured ArticleRead Full Article COVID-19: FINDING THE RIGHT FIT Identifying Potential Treatments Using a Data-Driven Approach Download the White PaperFeatured Drug
REMDESIVIR
Remdesivir, or GS-5734, is an adenosine triphosphate analog first described in the literature in 2016 as a potential treatment for Ebola. In 2017, its activity against the coronavirus family of viruses was also demonstrated. Remdesivir is also being researched as a potential treatment to SARS-CoV2, the coronavirus responsible forCOVID-19.
Targets (2)
Recent News/Blog Posts A YEAR IN REVIEW: DRUGBANK'S 2019 HIGHLIGHTS 2019 was a wild year for us, and we wanted to share some of our top highlights with you! DRUGBANK ACCEPTED INTO CREATIVE DESTRUCTION LAB - WEST 2019/20 COHORT Edmonton based startup, DrugBank, has been accepted into the 2019/20 Creative Destruction Lab (CDL) program year. CDL is a seed-stage program for massively scalable, science-based companies. DRUGBANK IS CROSSING THE POND! We are hopping on a red-eye this week headed to London, UK, to take part in the 2019 AI in Drug Development Congress. We’re really excited to be participating in the Congress, and can’t wait to meetyou.
USING DRUGBANK DATA IN AI DRUG DISCOVERY: A CASE STUDY High-quality data is the first step for training Machine-Learning (ML) and Artificial Intelligence (AI) algorithms, but obtaining this information is difficult as most knowledge about drugs exists within scientific publications in an unstructured text format. This is whereDrugBank comes in.
DRUGBANK FALL 2019 FEATURE RELEASE The DrugBank team is proud to announce our Fall 2019 Feature Release. Read more for exciting updates. DRUGBANK WINS PRAIRIE HIGH-GROWTH STARTUP OF THE YEAR AWARD BY STARTUPCANADA
DrugBank received the Startup Canada Prairie High-Growth Startup of the Year Award in Edmonton, presented by Mastercard Canada. CANNABINOIDS IN EPILEPSY: A NEW ERA OF TREATMENTS In a groundbreaking announcement, a Food and Drug Administration (FDA) advisory panel gave their unanimous recommendation in April 2018 for the approval of Epidiolex, a cannabis-derived product shown to be effective for the treatment of two forms of treatment-resistant childhood epilepsies. FROM DISCOVERY TO RESISTANCE TO PROGRESS New research points towards the possibility that the solution to our current antibiotic crisis may be patiently waiting to be discovered ina soil sample.
DRUGBANK PARTNERS WITH ONTOTEXT TO ACCELERATE PHARMA RESEARCH This partnership will provide a new and essential research tool for use in drug discovery and drug repurposing. KETAMINE: THE KEY TO TREATMENT RESISTANT DEPRESSION? Treatment of depression can be a complex blend of art and science. Here we explore Ketamine, a potentially ground-breaking drug for treatment-resistant depression. TIDEGLUSIB: FROM ALZHEIMER'S TO CARIES LESION NATURAL REPAIR Nowadays, it is fairly common in science to discover that a drug with an initial indication can be repurposed to target a completely different condition; this is the case with Tideglusib. NEW FEATURE: BIOPHARMACEUTICAL CLASSIFICATION Recently, we have been working on adding allergenics, vaccines, and other biopharmaceuticals to DrugBank. In order to allow easy filtering of these new datasets, we have created a simple biopharmaceutical classification system which we outline here. CFTR MODULATORS HELPING CF PATIENTS CATCH THEIR BREATH Orkambi and Kalydeco are members of a new generation of medications that are making history for people living with Cystic Fibrosis. Capable of correcting the underlying genetic defect that causes CF, Orkambi and Kalydeco can essentially override the mutation in a protein named Cystic Fibrosis Transmembrane Conductance Regulator, also known as CFTR. Affecting around 75 000 people globally, Cystic Fibrosis is the result of inheriting two copies of a CFTR mutation. NEW ANTIVIRALS PROVIDE HOPE FOR ERADICATION OF HEPATITIS C – IF YOUCAN AFFORD IT
Since the early 2010s we’ve been lucky enough to find ourselves in the golden age of antivirals. Highly potent and effective medications for the management of infectious diseases like Hepatitis C and HIV have revolutionized care and made treatments significantly more tolerable for patients. DRUGBANK IS OFFERED TO THE PUBLIC AS A FREELY AVAILABLE RESOURCE. Use and re-distribution of the data, in whole or in part, for commercial purposes (including internal use) requires a license. We ask that users who download significant portions of the database cite the DrugBank paper in any resulting publications.Cite DrugBank
DrugBank for Commercial UseCITING DRUGBANK
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2017 Nov 8. doi: 10.1093/nar/gkx1037.PubMed:29126136
Copy to clipboard
Law V, Knox C, Djoumbou Y, Jewison T, Guo AC, Liu Y, Maciejewski A, Arndt D, Wilson M, Neveu V, Tang A, Gabriel G, Ly C, Adamjee S, Dame ZT, Han B, Zhou Y, Wishart DS. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 2014 Jan 1;42(1):D1091-7.PubMed:24203711
Copy to clipboard
Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.PubMed: 21059682Copy to clipboard
Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.PubMed: 18048412Copy to clipboard
Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, Chang Z, Woolsey J. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006 Jan 1;34(Database issue):D668-72.PubMed: 16381955Copy to clipboard
About
* About DrugBank.ca
* Blog
* Wishart Research Group* Careers
* Terms of Use
* Privacy Policy
Support
* Help Center
* DrugBank.ca FAQs
* Contact Support
Commercial Data
* Clinical Drug Data * Scientific Drug Data* Contact Sales
This project is supported by the Canadian Institutes of Health Research (award #111062), Alberta Innovates - Health Solutions , and by The Metabolomics Innovation Centre (TMIC) , a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by Genome Alberta , Genome British Columbia, and Genome Canada
, a not-for-profit organization that is leading Canada's national genomics strategy with funding from the federal government. Maintenance, support, and commercial licensing is provided by OMx Personal Health Analytics, Inc. Designed by Educe Design & Innovation Inc.Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0